| Literature DB >> 27273729 |
T Siemeni1, A-K Knöfel1,2, N Madrahimov1, W Sommer1,2, M Avsar1, J Salman1, F Ius1, N Frank1, G Büchler1, D Jonigk3, K Jansson1, U Maus2,4, I Tudorache1, C S Falk5, A Haverich1,2, G Warnecke6,7.
Abstract
Experimentally, regulatory T cells inhibit rejection. In clinical transplantations, however, it is not known whether T cell regulation is the cause for, or an epiphenomenon of, long-term allograft survival. Here, we study naïve and alloantigen-primed T cell responses of clinical lung transplant recipients in humanized mice. The pericardiophrenic artery procured from human lung grafts was implanted into the aorta of NODrag-/- /IL-2rγc-/- mice reconstituted with peripheral blood mononuclear cells (PBMCs) from the respective lung recipient. Naïve or primed allogeneic PBMCs procured 21 days post-lung transplantation with or without enriching for CD4+ CD25high T cells were used. Transplant arteriosclerosis was assessed 28 days later by histology. Mice reconstituted with alloantigen-primed PBMCs showed significantly more severe transplant arteriosclerosis than did mice with naïve PBMCs (p = 0.005). Transplant arteriosclerosis was equally suppressed by enriching for autologous naïve (p = 0.012) or alloantigen-primed regulatory T cells (Tregs) (p = 0.009). Alloantigen priming in clinical lung recipients can be adoptively transferred into a humanized mouse model. Transplant arteriosclerosis elicited by naïve or alloantigen-primed PBMCs can be similarly controlled by potent autologous Tregs. Cellular therapy with expanded autologous Tregs in lung transplantation might be a promising future strategy. © Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.Entities:
Keywords: alloantigen; animal models: murine; basic (laboratory) research/science; clinical research/practice; cytokines/cytokine receptors; immunosuppression/immune modulation; lung (allograft) function/dysfunction; lung transplantation/pulmonology; rejection: chronic
Mesh:
Substances:
Year: 2016 PMID: 27273729 DOI: 10.1111/ajt.13905
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086